In patients with reduced left ventricular ejection fraction (LVEF), angiotensin II receptor blockers (ARBs) have been shown to decrease cardiovascular mortality and hospital admissions for heart failure. However, despite having different affinities for the AT1 receptor and different effects on outcomes, few ARBs have been compared head-to-head. This study aimed to compare the effects of […]